EMBI News and Press, Emerald Bioscience Inc From 12/16/20

Emerald Bioscience ([[EMBI]] -0.3%) has announced that its THC prodrug, THCVHS, optimized through a nanoemulsion formulation (THCVHS-NE) in animal models, demonstrated significantly better reduction of intraocular pressure ((IOP)) compared to the commercially approved standard of ca...

Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San Diego, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTC...

San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing proprietary molecules with strong clinical and commercial differentiation...

Emerald Bioscience ([[EMBI]] +0.8%) says that it is highly focused on advancing its lead compound THCVHS, a THC prodrug, for glaucoma into human studies. Anticipates to initiate first in-human study in Q3 2021 with data anticipated in early 2022.It also expects to commence addi...

Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection and comparison with leading glaucoma treatments Preclinical studies of CB...

San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class molecules with strong clinical and commercial differentiation, announced today that Punit Dhillon,...

San Diego, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class molecules with strong clinical and com...

Emerald Bioscience ( OTCQB:EMBI ) appointed  20-year biotech industry seasoned CEO Punit Dhillon, board chairman, as CEO, effective immediately; succeeding Brian Murphy, MD. More news on: Emerald Bioscience Inc., Healthcare stocks news, Read more ...

Renewed team and capital focused on advancing lead compound for glaucoma into clinical development San Diego, Calif, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical...

Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that it has raised approximately $7....